TDC
TVTX icon

Thompson Davis & Co’s Travere Therapeutics TVTX Stock Holding History

Thompson Davis & Co’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-250
Closed -$5K – 718
2017
Q4 		$5K Hold
250
– – 0.01% 527
2017
Q3 		$6K Buy
+250
New +$5.5K 0.01% 822

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Thompson Davis & Co's TVTX Position: Q1 2018 in Review

Thompson Davis & Co sold out of Travere Therapeutics (TVTX) in Q1 2018, closing a stake of 250 shares — an estimated $5K sold.

Thompson Davis & Co first reported a position in TVTX in Q3 2017 and held it in 2 quarters. The position peaked at $6K in Q3 2017. 119 funds tracked by Wall St. Rank hold TVTX as of Q1 2018.

  • Thompson Davis & Co reported no remaining Travere Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Travere Therapeutics shares in Q1 2018, an estimated $5K.
  • Thompson Davis & Co first reported a position in Travere Therapeutics in Q3 2017 and held it in 2 quarters.
  • Thompson Davis & Co's Travere Therapeutics position peaked at $6K in Q3 2017.
  • 119 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2018.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.